Evidence map›Paper›PMID 41000036›Full record

ArticleAIDS (London, England)2025

Suboptimal ART adherence, undetectable urine tenofovir, and higher C-reactive protein values.

Delaram Ghanooni, Megan J Heise, Kevin Sassaman, David V Glidden, Tyler Martinson, Shivani Mahuvakar, Dustin T Duncan, Keith J Horvath, Sabina Hirshfield, Renessa Williams and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Delaram GhanooniFlorida International University, Robert Stempel College of Public Health and Social Work, Miami, FL.
Megan J HeiseUniversity of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine.
Kevin SassamanUniversity of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine.
David V GliddenUniversity of California, San Francisco, Division of Epidemiology and Biostatistics, CA.
Tyler MartinsonUniversity of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine.
Shivani MahuvakarUniversity of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine.
Dustin T DuncanColumbia University, Mailman School of Public Health, Department of Epidemiology, New York City, NY.
Keith J HorvathSan Diego State University, Department of Psychology, San Diego, CA.
Sabina HirshfieldState University of New York - Downstate Health Sciences University, Department of Medicine, STAR Program Brooklyn, NY.
Renessa WilliamsUniversity of Miami, School of Nursing and Health Sciences, Coral Gables, FL.
Mallory O JohnsonUniversity of California, San Francisco, School of Medicine, San Francisco, CA.
Christian GrovCity University of New York, Graduate School of Public Health and Health Policy, Department of Community Health and Social Sciences, New York, NY, USA.
Monica GandhiUniversity of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine.
Adam W CarricoFlorida International University, Robert Stempel College of Public Health and Social Work, Miami, FL.
Matthew SpinelliUniversity of California, San Francisco, Division of HIV, Infectious Diseases, and Global Medicine.

Funding

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.UH3DA058304 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adam Wayne Carrico, Monica Gandhi · 2025 to 2026
$3.6M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.UG3DA058304 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARRICO, ADAM WAYNE, GANDHI, MONICA · 2023 to 2024
$2.0M
NIAID NIH HHS R01 AI143340NIAID NIH HHS R37 AI098472NIDA NIH HHS UG3 DA058304NIDA NIH HHS UH3 DA058304NIMHD NIH HHS L60 MD019900
6 · The paper itself

Abstract

Even with antiretroviral therapy, people with HIV often face residual immune activation and chronic systemic inflammation, heightening their risk for early-onset comorbidities such as cardiovascular disease. In a study of 492 men who have sex with men, suboptimal ART adherence, measured by undetectable urine tenofovir, was directly associated with elevated C-reactive protein, even after adjusting for viral suppression and stimulant use. These findings highlight the importance of adherence monitoring to reduce inflammation-related chronic health outcomes.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsC-Reactive ProteinHIV InfectionsMedication AdherenceTenofovirAdultHomosexuality, MaleHumansMaleMiddle AgedUrineAnti-HIV AgentsAnti-Retroviral AgentsC-Reactive ProteinTenofovir

Identifiers

PMID41000036
PMCPMC12479088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.